FMBA's innovation platforms Diagnostics and vaccine work

Oct 5

Skvortsova describes FMBA's platform and cluster approach since 2020, reporting growth from eight platforms by 2022 to 27, a 2.5–3-fold shorter innovation cycle during 2021–2026, nearly 700 intellectual results, 322 patents, 49 registered innovative medicines and 47 medical devices. She claims convective PCR can detect more than 200 markers or pathogens in under twenty minutes with sensitivity down to ten copies, and describes unknown-pathogen identification by metabarcoding and sequencing. She reports a birch-allergy vaccine registered last week, ragweed work, a meningococcal vaccine including serotype B and a recombinant dengue vaccine developed after a Nicaraguan presidential appeal, claiming a method to avoid antibody-dependent enhancement. She briefly mentions personalized cancer vaccines. She concludes that scaling requires industrial partners recruited as preclinical work nears completion after safety, efficacy and quality checks, and timely technology transfer. Novelty and efficacy claims remain attributed; no blanket clinical approval is inferred.

Skvortsova reports FMBA's platform and cluster programme growing to 27 platforms, a 2.5–3-fold shorter innovation cycle and numerous patents, registered drugs and devices over 2021–2026. She says large-scale production requires industrial partners and timely transfer as preclinical work nears completion after safety, efficacy and quality checks. Her result totals and leadership claims remain attributed; the statement does not grant blanket approval to every development mentioned.